Enalare Therapeutics Inc.
NJ
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- South Jersey Technology Park, 107 Gilbreth Pkwy, Mullica Hill, NJ 08062, USA
- Website
- enalare.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $810,132 |
| FY2025 | $0 |
| FY2024 | $4,974,417 |
| FY2023 | $469,302 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $810,132 |
Contract awards
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit)… | National Institute on Drug Abuse (NIH) | $8,136,760 |
Similar vendors
About the company
Enalare Therapeutics Inc. is a for-profit pharmaceutical company focused on developing respiratory stimulant therapeutics. The company has received several federal contract and grant awards from agencies like the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) to support its drug development efforts.
Through federal contracts, Enalare has worked on developing an "agnostic respiratory stimulant" as a medical countermeasure to treat respiratory depression. One major $50.8 million contract from HHS's Biomedical Advanced Research and Development Authority (BARDA) aims to advance Enalare's candidate respiratory stimulant towards FDA approval or licensure for this purpose. Another $749,000 firm-fixed price BARDA contract supports Enalare's research into host-directed therapeutics to mitigate long-term effects of lung injury under BARDA's Easy Broad Agency Announcement initiative.
On the federal grant side, Enalare received a $639,406 project grant from NIH's National Institute on Drug Abuse to fund Phase 1 and 2 clinical trials of its lead compound ENA-001. This grant is supporting research into ENA-001 as a potential treatment for respiratory depression caused by opioid or polysubstance overdose. The trials will characterize the pharmacokinetics, safety, and efficacy of intravenous and intramuscular dosing of ENA-001 in stimulating ventilation without reversing opioid analgesia or precipitating withdrawal. The results will guide further development of ENA-001 for this therapeutic indication.
Quick answers
Is Enalare Therapeutics Inc. registered in SAM.gov?
Yes. Enalare Therapeutics Inc.'s SAM.gov registration is active through September 9, 2027.
What is Enalare Therapeutics Inc.'s CAGE code?
Enalare Therapeutics Inc.'s CAGE code is 8G2D2, and its Unique Entity ID (UEI) is MDJFW877BCV6.
How much has Enalare Therapeutics Inc. received in federal contracts?
Federal contracts obligated $6,253,851 to Enalare Therapeutics Inc. in fiscal years 2023 through 2027.
What is Enalare Therapeutics Inc.'s most recent federal award?
Enalare Therapeutics Inc.'s most recent federal contract award is Enalare therapeutics: an agnostic respiratory stimulant for use as a medical countermeasure to treat respiratory… (75A50122C00072), from Office of the Assistant Secretary for Preparedness and Response, on September 22, 2022.
On GovTribe
See Enalare Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors